SVRA (Savara Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by SVRA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-24 | Robert Matthew Lutz | Chief Fin. & Operating Officer | A | — | — |
| 2026-06-22 | David L Lowrance | Chief Financial Officer | MIXED | — | — |
| 2026-03-20 | David L Lowrance | Chief Financial Officer | MIXED | — | — |
| 2026-02-17 | Joseph S McCracken | Director | M | — | — |
| 2025-12-19 | DAVID A RAMSAY | Director | Sell | — | — |
| 2025-12-16 | David L Lowrance | Chief Financial Officer | MIXED | — | — |
| 2025-12-16 | Kathleen R. McCabe | Chief Legal Officer | F | — | — |
| 2025-12-16 | Robert Matthew Lutz | Chief Operating Officer | F | — | — |
| 2025-12-16 | Anne Erickson | Chief Business Officer | F | — | — |
| 2025-12-16 | Matthew Pauls | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-12-11 | Matthew Pauls | CHIEF EXECUTIVE OFFICER | G | — | — |
| 2025-12-11 | An van Es-Johansson | Director | A | — | — |
| 2025-12-11 | Richard J Hawkins | Director | A | — | — |
| 2025-12-11 | Joseph S McCracken | Director | A | — | — |
| 2025-12-11 | Nevan C Elam | Director | A | — | — |
| 2025-12-11 | DAVID A RAMSAY | Director | A | — | — |
| 2025-12-04 | Yasmine Wasfi | Chief Medical Officer | F | — | — |
| 2025-12-04 | Nevan C Elam | Director | MIXED | — | — |
| 2025-11-17 | Richard J Hawkins | Director | M | — | — |
| 2025-10-22 | Yasmine Wasfi | Chief Medical Officer | A | — | — |
| 2025-06-23 | Richard J Hawkins | Director | Buy | — | — |
| 2025-06-02 | Joseph S McCracken | Director | Buy | — | — |
| 2025-04-01 | DAVID A RAMSAY | Director | Buy | — | — |
| 2025-02-14 | Robert Matthew Lutz | Chief Operating Officer | F | — | — |
| 2024-12-16 | DAVID A RAMSAY | Director | A | — | — |
| 2024-12-16 | Nevan C Elam | Director | A | — | — |
| 2024-12-16 | An van Es-Johansson | Director | A | — | — |
| 2024-12-16 | David L Lowrance | Chief Financial Officer | MIXED | — | — |
| 2024-12-16 | Richard J Hawkins | Director | MIXED | — | — |
| 2024-12-16 | Braden C. Parker | Chief Commercial Officer | A | — | — |
| 2024-12-16 | Matthew Pauls | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2024-12-16 | Raymond Dennis Pratt | Chief Medical Officer | A | — | — |
| 2024-12-16 | Joseph S McCracken | Director | A | — | — |
| 2024-12-16 | Anne Erickson | Chief Business Officer | MIXED | — | — |
| 2024-12-16 | Robert Matthew Lutz | Chief Operating Officer | A | — | — |
| 2024-11-20 | Joseph S McCracken | Director | Buy | — | — |
| 2024-11-18 | DAVID A RAMSAY | Director | Buy | — | — |
| 2024-11-12 | Raymond Dennis Pratt | Chief Medical Officer | F | — | — |
| 2024-10-22 | Anne Erickson | Chief Business Officer | F | — | — |
| 2024-09-27 | Braden C. Parker | Chief Commercial Officer | A | — | — |
| 2024-07-22 | Anne Erickson | Chief Business Officer | F | — | — |
| 2024-04-23 | Anne Erickson | Chief Business Officer | F | — | — |
| 2023-12-29 | David L Lowrance | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2023-12-29 | Matthew Pauls | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2023-12-29 | Nevan C Elam | Director | MIXED | — | — |
| 2023-12-18 | Raymond Dennis Pratt | Chief Medical Officer | A | — | — |
| 2023-12-15 | Joseph S McCracken | Director | A | — | — |
| 2023-12-15 | Matthew Pauls | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2023-12-15 | Nevan C Elam | Director | A | — | — |
| 2023-12-15 | David L Lowrance | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 24,471,264 | — |
| — | 10%+ Owner | 24,471,264 | — |
| — | 10%+ Owner | 24,471,264 | — |
| — | 10%+ Owner | 24,471,264 | — |
| — | 10%+ Owner | 24,471,264 | — |
| — | 10%+ Owner | 24,471,264 | — |
| — | 10%+ Owner | 24,471,264 | — |
| — | 10%+ Owner | 24,471,264 | — |
| — | 10%+ Owner | 24,471,264 | — |
| — | 10%+ Owner | 24,471,264 | — |
| — | Director | 2,533,642 | — |
| — | CHIEF EXECUTIVE OFFICER | 1,188,050 | — |
| — | Chief Financial Officer | 896,297 | — |
| — | Chief Legal Officer | 519,232 | — |
| — | Chief Executive Officer | 498,028 | — |
| — | Director | 429,179 | — |
| — | Chief Business Officer | 371,712 | — |
| — | Chief Medical Officer | 340,050 | — |
| — | Chief Fin. & Operating Officer | 328,977 | — |
| — | Director | 302,644 | — |
| — | CHIEF MEDICAL OFFICER | 300,000 | — |
| — | Chief Medical Officer | 168,008 | — |
| — | See Remarks | 167,569 | — |
| — | Director | 161,326 | — |
| — | Director | 106,887 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SVRA quote page; the site-wide leaderboard is on the insider transactions hub.